AmpliPhi punts a synthetic biology partnership with Intrexon


On second thought, AmpliPhi Biosciences isn’t sold on Intrexon’s synthetic biology tech for its anti-infectives after all. Just three days ahead of the third anniversary for their tie-up, the San Diego-based biotech is calling it quits and terminating the pact.

“We thank Intrexon for their financial support dating back to 2013,” said CEO Scott Salka in a statement. “Terminating this exclusive collaboration with Intrexon allows us to take advantage of the rapid advancements being made in the field of synthetic biology and frees us to partner with best-in-class technologies for genetically modifying phages to further improve their ability to conquer pathogenic bacteria resistant to current antibiotics.”

Salka arrived at the company a little less than a year ago.


Digitize remote site monitoring with Box

Box will discuss how your life sciences organization can continue to propel therapies & devices through the value chain with faster and even more secure site monitoring and auditing.

AmpliPhi has been working on bacteriophages, viruses that are designed to “eat” specific bacteria. In an age of rising resistance to existing antibiotics, it’s a new approach that the biotech hopes can be better targeted than far less discriminating antibiotics.

The end of the deal isn’t likely to have a big impact on Intrexon, which has been furiously ramping up new companies and pacts in recent years in a broad range of R&D fields. Just yesterday Intrexon ramped up two new companies that will take funding from the related Harvest Intrexon Enterprise Fund. The two new companies are:

    •    Relieve Genetics, which will focus on a “breakthrough, non-opioid gene therapy approach for neuropathic pain”; and

    •    Exotech Bio, which will use “a novel exosome-based platform for delivering therapeutic RNA to treat select cancer indications.”

- here's the release


Suggested Articles

Journey Colab launches with $3 million from Apollo Projects to develop a pipeline of psychedelic compounds through a new development model.

Forma's lead asset, an IDH1 inhibitor, cleared cancer in one-third of patients with relapsed or refractory acute myeloid leukemia.

A type of white blood cell known as a granulocyte secretes growth factors that help axons of the central nervous system regenerate, researchers found.